Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016

NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0176366/Atrial-Fibrillation---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist's new report, "Atrial Fibrillation – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global atrial fibrillation therapeutics market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global atrial fibrillation market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides a valuable insight into the pipeline products within the global atrial fibrillation therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- Annualized global atrial fibrillation therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.

- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include Factor Xa Inhibitors, direct thrombin inhibitors, A1 adenosine receptor agonists, multiple and selective ion channel blockers and gap junction inhibitors.

- Analysis of the current and future market competition in the global atrial fibrillation therapeutics market. Key market players covered are Bayer Healthcare, Proctor and Gamble, Boehringer Ingelheim, Sanofi Aventis, Cardiome Pharma Corp and Astellas Pharma US and Xention Ltd.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with atrial fibrillation.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global atrial fibrillation therapeutics market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments, and companies likely to impact the global atrial fibrillation therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

- What's the next big thing in the global atrial fibrillation market landscape? Identify, understand, and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Atrial Fibrillation: Market Characterization 6

2.1 Overview 6

2.2 Atrial Fibrillation Market Size 6

2.3 Atrial Fibrillation Market Forecast and CAGR 7

2.4 Drivers and Barriers for the Atrial Fibrillation Market 8

2.4.1 Drivers of the Atrial Fibrillation Market 8

2.4.2 Barriers for the Atrial Fibrillation Market 9

2.5 Opportunity and Unmet Need 9

2.6 Key Takeaway 10

3 Atrial Fibrillation Market: Competitive Assessment 11

3.1 Overview 11

3.2 Strategic Competitor Assessment 11

3.3 Product Profile for the Major Marketed Products in the Atrial Fibrillation Market 12

3.3.1 Multaq 12

3.3.2 Tikosyn 13

3.3.3 Tambocor 14

3.3.4 Coumadin (Warfarin- Anticoagulants) 15

3.3.5 Betapace AF 16

3.4 Key Takeaway 17

4 Atrial Fibrillation: Pipeline Assessment 18

4.1 Overview 18

4.2 Strategic Pipeline Assessment 18

4.2.1 Technology Trends Analytic Framework 18

4.3 Atrial Fibrillation Therapeutics – Promising Drugs under Clinical Development 20

4.4 Drugs under Clinical Development 20

4.4.1 Xarelto 20

4.4.2 Pradaxa 21

4.4.3 Stedicor 22

4.4.4 Kynapid 23

4.4.5 Edoxaban 24

4.5 Atrial Fibrillation Therapeutics Market – Clinical Pipeline by Mechanism of Action 24

4.6 Atrial Fibrillation Pipeline – Pipeline by Clinical Phases of Development 25

4.6.1 Atrial Fibrillation Therapeutics – Phase III Clinical Pipeline 26

4.6.2 Atrial Fibrillation Therapeutics – Phase II Clinical Pipeline 27

4.6.3 Atrial Fibrillation Therapeutics – Phase I Clinical Pipeline 27

4.6.4 Atrial Fibrillation Therapeutics – Preclinical Pipeline 27

4.7 Discontinued / Suspended Drugs for Atrial Fibrillation 28

4.8 Key Takeaway 28

5 Atrial Fibrillation Market: Implications for Future Market Competition 29

6 Atrial Fibrillation Market: Future Players in the Atrial Fibrillation Market 30

6.1 Introduction 30

6.2 Cardiome Pharma Corp and Astellas Pharma US, Inc 30

6.2.1 Overview 30

6.2.2 Business Description 31

6.2.3 CV Portfolio 31

6.2.4 Atrial Fibrillation Product Portfolio 31

6.3 Sanofi Aventis 33

6.3.1 Overview 33

6.3.2 Business Description 33

6.3.3 CV Portfolio 34

6.4 Daiichi Sankyo Company, Limited 34

6.4.1 Overview 34

6.4.2 Business Description 34

6.4.3 CV Portfolio 35

6.4.4 Atrial Fibrillation product portfolio 35

6.5 Boehringer Ingelheim 36

6.5.1 Overview 36

6.5.2 Business Description 36

6.5.3 CV Portfolio 36

6.5.4 Atrial Fibrillation Product Portfolio 37

6.6 Procter and Gamble 37

6.6.1 Overview 37

6.6.2 Business Description 37

6.6.3 CV Portfolio 38

6.6.4 Atrial Fibrillation Product Portfolio 38

6.7 Bayer Healthcare 39

6.7.1 Overview 39

6.7.2 Business Description 39

6.7.3 CV Portfolio 39

6.7.4 Atrial Fibrillation Product Portfolio 39

7 Atrial Fibrillation Market: Appendix 41

7.1 Definitions 41

7.2 Acronyms 41

7.3 Research Methodology 42

7.3.1 Coverage 43

7.3.2 Secondary Research 43

7.3.3 Forecasting 43

7.3.4 Primary Research 46

7.3.5 Expert Panels 46

7.4 Contact Us 46

7.5 Disclaimer 46

7.6 Sources 47

1.1 List of Tables

Table 1: Global Atrial Fibrillation Market Revenues, 2001-2009 7

Table 2: Global Atrial Fibrillation Market Forecast, 2009-2016 8

Table 3: Strategic Competitor Assessment of the Major Marketed Products in Atrial Fibrillation, 2010 11

Table 4: A summary of Key Phase III clinical trials for Multaq 13

Table 5: Major Marketed Products in the Atrial Fibrillation Market, 2010 17

Table 6: Atrial Fibrillation Therapeutics –Promising Drugs Under Clinical Development, 2010 20

Table 7: Clinical study details on ROCKET-AF with Xarelto 21

Table 8: Atrial Fibrillation Therapeutics – Phase III Clinical Pipeline, 2010 26

Table 9: Atrial Fibrillation Therapeutics – Phase II Clinical Pipeline, 2010 27

Table 10: Atrial Fibrillation Therapeutics – Phase I Clinical Pipeline, 2010 27

Table 11: Atrial Fibrillation Therapeutics – Preclinical Pipeline, 2010 27

Table 12: List of Discontinued Drugs for Atrial Fibrillation, 2010 28

Table 13: Cardiome and Astellas Pharma Inc. – CV and Atrial Fibrillation Pipeline, 2010 31

Table 14: Sanofi-Aventis – CV and Atrial Fibrillation Pipeline, 2010 34

Table 15: Daiichi Sankyo Co. Ltd – CV and Atrial Fibrillation Pipeline, 2010 35

Table 16: Boehringer Ingelheim – Atrial Fibrillation Pipeline, 2010 36

Table 17: P&G – Atrial Fibrillation Pipeline Products, 2010 38

Table 18: Bayer HealthCare – CV and Atrial Fibrillation Pipeline, 2010 39

Table 19: Clinical study details on ROCKET-AF with Xarelto 40

1.2 List of Figures

Figure 1: Global Atrial Fibrillation Market Revenues, 2001–2009 7

Figure 2: Global Atrial Fibrillation Market Forecast, 2009-2016 8

Figure 3: Opportunity and Unmet Need in the Atrial Fibrillation Market, 2010 10

Figure 4: Technology Trends Analytic Framework of the Atrial Fibrillation Pipeline, 2010 19

Figure 5: Technology Trends Analytic Framework of Atrial Fibrillation Pipeline – Description, 2010 19

Figure 6: Atrial Fibrillation Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 25

Figure 7: Atrial Fibrillation Pipeline by Phase of Clinical Development, 2010 25

Figure 8: Implications for Future Market Competition in the Atrial Fibrillation Market, 2010 29

Figure 9: Atrial Fibrillation Therapeutics Market – Clinical Pipeline by Company, 2010 30

Figure 10: GlobalData Methodology 42

Figure 11: GlobalData Market Forecasting Model 45

Companies Mentioned

Cardiome Pharma Corp and Astellas Pharma US, Inc

Sanofi Aventis

Daiichi Sankyo Company, Limited

Boehringer Ingelheim

Procter and Gamble

Bayer Healthcare

To order this report:

Drug and Medication Industry: Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker